Company Filing History:
1 out of 284 
1 out of 116 
Years Active: 2023
Title: Mamta Chabria: Innovator in Tumor and Fibrosis Diagnosis and Therapy
Introduction
Mamta Chabria is a distinguished inventor based in Zurich, Switzerland. She has made significant contributions to the field of medical diagnostics and therapeutics, particularly in the context of tumor and fibrosis treatment. Her innovative work has led to the development of a unique composition that holds promise for improving patient outcomes in various diseases.
Latest Patents
Mamta Chabria holds a patent for "Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy." This invention is directed towards a composition that includes at least one fibronectin binding polypeptide (FnBP) linked to a diagnostic or therapeutic agent. The patent also encompasses a nucleic acid encoding a fusion polypeptide comprising the FnBP linked to a therapeutic agent, along with a corresponding recombinant vector and host cell. The invention aims to provide a kit that includes the FnBP, diagnostic or therapeutic agents, and optional chemical agents for linking these components. This composition is intended for therapeutic or prophylactic treatment of diseases associated with abnormal fibronectin accumulation, such as cancer, fibrosis, or immune diseases.
Career Highlights
Throughout her career, Mamta Chabria has worked with prestigious institutions, including ETH Zurich and the Paul Scherrer Institute. Her research has focused on the intersection of molecular biology and therapeutic applications, leading to advancements in the understanding and treatment of complex diseases.
Collaborations
Mamta has collaborated with notable colleagues, including Alessandra Moscaroli and Simon Arnoldini. These partnerships have fostered a collaborative environment that enhances the innovation process and contributes to the advancement of medical science.
Conclusion
Mamta Chabria's contributions to the field of tumor and fibrosis diagnosis and therapy exemplify her commitment to innovation in medical science. Her patented work on fibronectin-binding peptides represents a significant step forward in the development of targeted therapies for serious health conditions.